ArticleScientific reports2025
ZFP36 regulates the osteogenic differentiation of adipose-derived mesenchymal stem cells in osteoporosis by mediating KLF3 mRNA degradation.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The ZFP36 Family as Post-Transcriptional Regulators in Physiology and Disease.International journal of molecular sciences · 2026Review
- Functional extracellular vesicles enable injectable hydrogels with stable osteogenic properties for minimally invasive bone defect repair.Scientific reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Osteoporosis is one of the most common bone-related diseases in which osteogenic differentiation plays a key role. Adipose-derived mesenchymal stem cells (ADMSCs), as one of the important sources of bone formation, can differentiate into osteoblasts under appropriate conditions. To investigate the effect and potential mechanism of ZFP36 on osteogenic differentiation of ADMSCs in osteoporosis by regulating the stability of KLF3 mRNA. In this study, an osteoporosis rat model was established by ovariectomy (OVX), and the expression level of KLF3 in bone tissue was detected by RT-qPCR and immunohistochemistry (IHC). To further investigate the effect of KLF3 gene knockdown on bone health in osteoporotic rats. In vitro, KLF3 over-expression was performed on ADMSCs, and the effect of KLF3 knockdown on osteogenic differentiation of ADMSCs was evaluated by alkaline phosphatase (ALP) activity assay and alizarin red S staining. In addition, RNA pull-down, dual luciferase reporter gene, RIP and Actinomycin D treatment were used to explore the regulatory mechanism of ZFP36-mediated KLF3 mRNA degradation in osteogenic differentiation. Finally, the effect of ZFP36 on osteogenic differentiation and its interaction with KLF3 were further verified by interfering with ZFP36/KLF3 expression in rats in vivo and in vitro. In the osteoporotic rat model, KLF3 expression was significantly downregulated in bone tissue. Over-expression of KLF3 in ADMSCs significantly increased KLF3 protein level but inhibited osteogenic differentiation. In contrast, the over-expression of ZFP36 significantly promoted the osteogenic differentiation of ADMSCs, and the expression level of KLF3 was significantly reduced under this condition. ZFP36 accelerates KLF3 degradation by directly binding KLF3 mRNA. Inhibition of ZFP36 inhibited osteogenic differentiation of cells by up-regulating KLF3, and osteogenic differentiation was promoted after KLF3 knockdown. In animal experiments, over-expression of ZFP36 significantly improved BMD, bone volume, and trabecular bone architecture in osteoporotic rats, while over-expression of KLF3 reversed these improvements. ZFP36 promotes the osteogenic differentiation of ADMSCs by mediating the degradation of KLF3 mRNA and provides a potential molecular target for the treatment of osteoporosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.